Format

Send to

Choose Destination
J Biol. 2009;8(3):30. doi: 10.1186/jbiol134. Epub 2009 Apr 15.

Exploiting the promiscuity of imatinib.

Author information

1
Department of Medicine and Division of Hematology-Oncology, 3855 Health Sciences Drive, University of California-San Diego, La Jolla, CA 92093, USA.

Erratum in

  • J Biol. 2010;8:82.

Abstract

The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 A crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor.

PMID:
19435483
PMCID:
PMC2689438
DOI:
10.1186/jbiol134
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center